PHIO PHARMACEUTICALS CORP. Phio Pharmaceuticals Corp. announced that its clinical development partners, AgonOx Inc. and Providence Cancer Institute of Oregon, have dosed their first patient in an Adoptive Cell Therapy clinical trial. This first-in-human trial is investigating the safety and the potential for enhanced therapeutic benefit from the administration of AgonOx?s AGX148 'double positive' (DP) CD8 tumor-infiltrating lymphocytes (TIL) alone and in combination with Phio's PD-1 silencing PH-762 in patients with melanoma and other advanced solid tumors.
More information about this clinical trial is available at clinicaltrials.gov. The clinical trial is one of two studies cleared by the FDA which will utilize Phio?s lead product candidate, PH-762.
